By Fineline Cube 
China-based Sinocelltech Group Ltd (SHA: 688520) announced that it has received clearance from the National Medical Products Administration (NMPA) to conduct a clinical study for its in-house developed SCTB39-1. This multi-target immunotherapeutic trispecific antibody (TriAb) is intended for patients with advanced malignant solid tumors and will be investigated as a monotherapy.
Clinical Study Details
The clearance from NMPA allows Sinocelltech to proceed with clinical trials to evaluate the safety and efficacy of SCTB39-1 in treating advanced malignant solid tumors. As a TriAb, SCTB39-1 is designed to engage multiple therapeutic targets simultaneously, potentially enhancing the immune system’s ability to target and eliminate cancer cells.-Fineline Info & Tech